建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。
Company Profile
Panlabs began as Panlabs Taiwan Ltd, founded in 1971 by Mr. Hsi-Lin Chen, Dr. Merle Pindell, and Dr. Joseph Lein in Taipei, Taiwan. In 2005, the core team of the fermentation department, led by Mr. Benny Hu, branched off, leading to the establishment of Panlabs Fermentation, which was later renamed Panlabs Biologics in June 2013.
Panlabs is a contract research organization (CRO) with over 45 years of experience in strain improvement. Since 1975, We have successfully completed commissioned projects for 105 clients, totaling over 300 projects. Our service focuses on the development of high-yield strains and fermentation process that can be scaled up for commercial production. In addition to providing customized R&D services for a variety of industries, Panlabs also provides tailor-made transfer technology, scale-up production services, and business models such as strain and technology licensing according to our clients’ needs. Each project is executed by a dedicated team that provides the best service, ensures efficient R&D progress, and fulfills the promise of absolute confidentiality.
We serve clients from all over the world, including many internationally renowned pharmaceutical and biotechnology companies. In North America, our customers include Eli Lilly, Merck&Co, Scherning Plough (BMS), Pfizer, Agennix, Warp Drive Bio, and Zafgen; in Europe, we have GlaxoSmithKline, Sterling Drug, Hoechst (Sanofi), Fine Agrochemical, Gist-Brocades, and Finnish Sugar (Cultor); in Asia, we serve Mercian (Sanraku), Daiichi Sankyo, Hindustan Antibiotics, Merind (Wockhardt), Hisun Pharmaceutical Co, Chunghwa Chemical Synthesis & Biotech, Yung Shin Pharmaceutical Industrial Co, and Formosa Laboratories Inc., etc.
Another invaluable asset is our diverse and specific microbial library, which offers more than 10,000 strains of Fungi and Actinomycetes respectively. After systematic strain identification and screening, valuable strains could be selected for the application in food, biotechnology, medicine, environmental protection, materials, and other relevant industries. This will assist clients in developing new applications and scheduling optimization.
Panlabs will uphold the core values that have guided us for more than 45 years and continue to enhance our R&D capabilities. Providing total solutions and creating the greatest value for our clients, we position ourselves as a global leader in strain improvement and biotechnology research.
Company advantage
45+ years of microbial strain improvement and development
- Random mutation
- High Throughput Mutants Screening (HTMS)
- Random and rational selection strategies
- Combination of random mutation and genetic engineering platforms
- Combination of strain improvement and media optimization
Optimizing the fermentation process of high-value natural products
- Increase yield
- Reduce impurities
- Scalable and robust strains
- Upstream and down stream process development
Worldwide-Based Microbial Library
- ~10,000 Fungi & ~10,000 Actinomycetes
- Apply for bio-active compound discovery
- Diversified geographical and environmental conditions
- Not subject to Nagoya Protocol
Customized service and demand orientation
- Feasibility study or integrated project
- Fee for service or flexible payment
- Technology transfer
- Assist for market access
Company history
-
1971
Mr. Shi-Lin Chen, Dr. Merle Pindell, and Dr. Joseph Lein found Panlabs Taiwan Ltd in Taipei, Taiwan, conducting pharmacological research, drug efficacy evaluation, and drug development. -
1975
Established fermentation laboratories to engage in microbial strain improvement and fermentation technology. -
1983
Established a molecular biotechnology laboratory in Seattle and renamed as Panlabs International. -
2005
Divestment of core fermentation team into Panlabs Fermentation. -
2013
Renamed as Panlabs Biologics Inc. -
2014
Commenced miniaturized culture, introduced automatic liquid handling system, and improved strain screening throughput. -
2015
Authorization of MCFG (CAS.No:235114-32-6) producing strains and fermentation process to pharmaceutical company. -
2020
Commenced payload intermediate of ADC supply business for clinical trial.2020 Authorization of Staurosporine/Midostaurin producing strains, fermentation, downstream process and semisynthesis process to pharmaceutical company. -
2021
Authorization of penicillin producing strains and fermentation process to pharmaceutical company.
